Pre-transplant Rituximab is associated with a greatly reduced risk of Epstein-Barr virus reactivation following allogeneic stem cell transplantation
David Burns, Shabeeha Rana, Andrew Howman, Sandeep Nagra, Janice Ward, Husam Osman, Yusri Taha, Jenny Byrne, Emma Das-Gupta, Manoj Raghavan, Ram Malladi, Mark Cook, Premini Mahendra, Nigel H Russell, Charles Craddock, Christopher Fox, Sridhar Chaganti
Research output: Contribution to conference (unpublished) › Abstract › peer-review
Fingerprint
Dive into the research topics of 'Pre-transplant Rituximab is associated with a greatly reduced risk of Epstein-Barr virus reactivation following allogeneic stem cell transplantation'. Together they form a unique fingerprint.